

# TRANSFORMATIVE THERAPIES | TARGETING CANCER


## QUICK FACTS

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops, and commercializes transformative medicines targeting cancer to make a meaningful difference in people's lives.

ADCETRIS® (brentuximab vedotin) and PADCEV™ (enfortumab vedotin-ejfv) use the company's industry-leading antibody-drug conjugate (ADC) technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved for certain types of CD30-expressing lymphomas, and PADCEV is approved to treat certain types of metastatic urothelial cancer. TUKYSA™ (tucatinib) is a small molecule tyrosine kinase inhibitor and is approved for certain HER2-positive metastatic breast cancers.

The company has a pipeline of novel targeted therapies at various stages of preclinical and clinical testing, as well as continuing development of our approved medicines. We also are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. For more information, visit [www.seattlegenetics.com](http://www.seattlegenetics.com) and follow @SeattleGenetics on Twitter.

Our ADC technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.



Various combinations of these novel modalities are likely to be the future of treatment in oncology

**YEARS:** 22

**SIZE:** Largest biotechnology company with headquarters in the Pacific Northwest

**EMPLOYEES:** 1,800+

**PASSION:** Helping people with cancer

**LEADERS IN:** Antibody-drug conjugate (ADC) technology

**OUR MEDICINES:**

**ADCETRIS®** (brentuximab vedotin) approved for adults with certain types of CD30-expressing lymphomas

**PADCEV™** (enfortumab vedotin-ejfv) approved to treat certain types of metastatic urothelial cancer

**TUKYSA™** (tucatinib) approved to treat certain HER2-positive metastatic breast cancers

**RESEARCH & DEVELOPMENT:**

>750 scientists dedicated to developing our next innovations, and medical and clinical researchers focused on improving patient outcomes with targeted treatment options, including multiple unique programs in ongoing clinical trials

**COLLABORATIONS:** Multiple ADC technology licensing agreements; co-development collaborations with other oncology industry leaders

**LOCATIONS:** Headquartered in Bothell, Washington, with offices in California, Switzerland, and the European Union

For more information on our company, our medicines, and our robust pipeline, we encourage you to visit [www.seattlegenetics.com](http://www.seattlegenetics.com) and follow @SeattleGenetics on Twitter.

## ADVANCING LATE-STAGE CLINICAL TRIALS AND AN EXPANDING DEVELOPMENT PORTFOLIO

PROGRAM / TUMOR TYPE	PHASE 1	PHASE 2	PHASE 3	PARTNER
<b>Brentuximab vedotin</b>				
Frontline Hodgkin lymphoma (HL)	Advanced HL (ADCETRIS, nivolumab and AD)			
Frontline HL or PTCL (unfit for combo chemotherapy)	Single-agent ADCETRIS			
Relapsed HL and PTCL	Retreatment with ADCETRIS			
Relapsed HL (pediatrics)	CheckMate 744: Combination with nivolumab			
Second-line HL	Combination with nivolumab			
Relapsed NHL	CheckMate 436: Combination with nivolumab			

<b>Enfortumab Vedotin</b>				
Metastatic urothelial cancer	EV-302: Combination with pembrolizumab with or without chemotherapy in untreated mUC			
	EV-301: Post PD(L)-1 and post platinum chemotherapy			
		EV-201: Cohort 2 post PD(L)-1 and platinum naive and cisplatin ineligible		
Metastatic solid tumors	EV-202: Previously treated locally advanced or metastatic solid tumors			
First-line metastatic and muscle invasive urothelial cancer	EV-103: Urothelial cancer (monotherapy and with other agents)			

<b>Tucatinib</b>				
Metastatic HER2+ breast cancer	HER2CLIMB-02: Combination with T-DM1			
Metastatic HER2+ colorectal cancer	MOUNTAINEER: Combination with trastuzumab			
Neoadjuvant breast cancer	I-SPY 2			

<b>Tisotumab Vedotin</b>				
Recurrent/metastatic cervical cancer	innovaTV 204	Pivotal		
First-line cervical cancer	innovaTV 205			
Locally advanced solid tumors (Japan only)	innovaTV 206			
Other solid tumors	innovaTV 207			
Ovarian cancer	innovaTV 208			

For a more comprehensive list of trials including, several earlier-stage proprietary targeted therapies, visit our website for details: [www.seattlegenetics.com](http://www.seattlegenetics.com)

These are investigational uses/agents and efficacy/safety have not been established. There is no guarantee that these agents will receive regulatory approval and become commercially available for uses being investigated.